Verona Pharma Plc has announced the appointment of Richard Hennings to the company’s senior management team as commercial director. Verona develops treatments for respiratory disease and recently announced collaborations to develop inhaled formulations for its lead product for chronic obstructive pulmonary disease (COPD).
Mr Hennings previously held positions at AstraZeneca Plc, Novartis, and Gilead Sciences Inc. At Gilead he was involved in developing products
for cystic fibrosis and COPD.
Verona Pharma announced the appointment on 31 March 2017.
Copyright 2017 Evernow Publishing Ltd